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Human immunodeficiency virus (HIV) infection is, with advancing 
immunosuppression, a risk factor for the development of heart 
failure due to dilated cardiomyopathy.1 In Africa, cross-sectional 
echocardiographic studies of HIV-infected individuals suggest a 
prevalence of cardiomyopathy varying from 9% in ambulant persons 
to 57% in hospitalised patients.2 Patients with HIV infection and 
dilated cardiomyopathy have a much worse prognosis than HIV-
positive individuals with normal cardiac function. The negative 
prognostic impact of cardiac dysfunction in people living with HIV 
is reflected by a median survival to AIDS-related death of 101 days 
in patients with cardiomyopathy compared with 472 days in patients 
with a normal heart by echocardiography at a similar stage of 
infection without antiretroviral treatment.3 
The cause of cardiomyopathy in black African patients infected 
with HIV remains largely unknown, although several predisposing 
factors have been identified.1,4 These include low socio-economic 
status, longer duration of HIV infection, lower CD4 cell count, higher 
viral load, low plasma selenium level, and advanced stage of HIV 
disease.5 Malnutrition has been postulated to be a contributory factor 
in the development of cardiomyopathy in HIV-infected individuals, 
but to the best of our knowledge the association of nutritional status 
with HIV-associated cardiomyopathy has not been established in 
appropriately designed studies.5
We conducted a cross-sectional study among HIV-infected adults 
to determine whether there is an association between nutritional 
status, measured by simple anthropometric criteria that can be 
applied in routine clinical practice, and HIV-related cardiomyopathy. 
This investigation of the relationship between nutritional status and 
cardiomyopathy in HIV-positive patients may be relevant in the 
development of new therapeutic strategies, including restoration of 
adequate myocyte nutrition as a goal in the treatment of patients 
suffering from HIV-related heart failure. 
Methods
Design
This was a cross-sectional study of 17 HIV-positive patients with 
cardiomyopathy and a comparison group of 18 HIV-positive 
individuals with no cardiomyopathy. The study was approved by the 
University of Cape Town (UCT) Health Sciences Faculty Human 
Research Ethics Committee (REC REF 016/2002), and all participants 
gave written informed consent.
Selection of participants
HIV-positive patients with and without cardiomyopathy were 
recruited from HIV clinics at Groote Schuur, New Somerset and 
G F Jooste Hospitals in Cape Town. Clinic attendees over the age 
of 18 years were invited to attend the Cardiac Clinic at Groote 
Schuur Hospital for clinical evaluation and examination by two-
dimensional guided M-mode echocardiography to identify those 
with cardiomyopathy. The two groups were matched for ethnicity as 
part of a study of genetic risk factors for cardiomyopathy in people 
with HIV infection.6 One experienced echocardiographer carried out 
all the echocardiographic examinations, using a calibrated ultrasound 
machine with a 2.5 MHz transducer with subjects in the left lateral 
position. The echocardiographic examinations were read by one 
cardiologist (BMM).
Patients with dilated cardiomyopathy (a fractional shortening of 
<25% and left ventricular internal dimension >112% of predicted, 
according to Henry’s formula) or patients with left ventricular 
dysfunction (a fractional shortening of <25% and normal ventricular Corresponding author: B M Mayosi (bongani.mayosi@uct.ac.za) 
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The cause of cardiomyopathy in patients infected with the human 
immunodeficiency virus (HIV) remains largely unknown, although 
a number of predisposing factors have been identified. Malnutrition 
has been postulated to be a contributory factor, but the association of 
anthropometric measures of nutritional status with HIV-associated 
cardiomyopathy has not been established.
Method. We investigated the association between anthropometric 
measures of nutritional status and cardiomyopathy in HIV-positive 
individuals in a cross-sectional case comparison study.
Results.  Seventeen cases of HIV-associated cardiomyopathy 
and a comparison group of 18 HIV-positive individuals without 
cardiomyopathy were studied. There was no significant difference 
between the two groups in age, gender, CD4 cell count, HIV RNA 
viral load or World Health Organization (WHO) clinical stage of 
HIV disease. Patients with HIV-associated cardiomyopathy had 
evidence of undernutrition compared with HIV-infected people 
without cardiomyopathy, as evidenced by a significantly lower body 
mass index (BMI) (20.9 kg/m2 v. 27.0 kg/m2, p=0.02), mid-upper 
arm circumference (26.2 cm v. 27.3 cm, p=0.02), and bone-free 
arm muscle area (26.7 cm2 v. 32.8 cm2, p=0.02). However, in a 
multivariate stepwise logistic regression model, a lower BMI was the 
only independent anthropometric risk factor for cardiomyopathy 
(odds ratio 0.76, 95% confidence interval 0.64 - 0.97, p=0.02).
Conclusion. A lower BMI is associated with cardiomyopathy in 
people who are living with HIV.
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dimensions) were included in the study.7 Patients with valvular heart 
disease, hypertension, ischaemic, pericardial or congenital heart 
disease, diabetes or alcoholic cardiomyopathy and women who 
fulfilled the criteria for peripartum cardiomyopathy were excluded. 
Treatment with antiretroviral agents that have been implicated in 
cardiomyopathy8 was also grounds for exclusion. 
Normal heart function was confirmed by echocardiography in all 
individuals in the comparison group. 
Laboratory tests
CD4 cell counts were obtained by lymphocyte immunophenotyping 
using a flow cytometer in the Immunology Laboratory at Groote 
Schuur Hospital. The HIV viral load was measured by a quantitative 
polymerase chain reaction assay of viral genomic RNA using the 
Nasba kit in the Division of Virology at the University of Cape 
Town.
Assessment of nutritional status
The following anthropometric measurements were taken by the 
same observer: body weight (on an electronic scale to the nearest 0.2 
kg), height (on a portable stadiometer to the nearest 1 mm, patient 
without shoes, feet parallel), mid-upper arm circumference (MUAC) 
(measured to the nearest 1 mm on the left arm using a standardised 
measuring tape – normal range is >232 mm for women and >243 mm 
for men), and triceps skinfold thickness (TSF) (to the nearest 0.2 mm 
using a Harpender caliper). Body mass index (BMI) (weight/height2, 
normal range 18.5 - 24.9) and bone-free arm muscle area (BF-AMA) 
(MUAC–(3.14×TSF)) were calculated.9,10 
Statistical methods
Categorical variables were compared using the χ2 test and continuous 
variables using the non-parametric Mann-Whitney test. The 
multivariate stepwise logistic regression model was used to identify 
independent anthropometric risk factors for cardiomyopathy. All 
tests were double-sided, and a p-value of <0.05 was considered 
significant.
Results
The clinical characteristics and nutritional status of the 17 patients 
with HIV-associated cardiomyopathy and the 18 HIV-infected 
individuals without cardiomyopathy are presented in Table I. There 
was no significant difference between the two groups with respect 
to age, gender, CD4 cell count, HIV viral load or World Health 
Organization clinical stage of HIV disease. 
Although most participants presented with anthropometric 
parameters within the normal range, HIV-positive patients with 
cardiomyopathy had significantly lower values compared with HIV-
positive patients without cardiomyopathy: BMI 20.9 kg/m2 v. 27.0 
kg/m2, p=0.02; MUAC 26.2 cm v. 27.3 cm, p=0.02; and BF-AMA 
26.7 cm2 v. 32.8 cm2, p=0.02. However, in a multivariate stepwise 
logistic regression model, a lower BMI was the only independent 
anthropometric risk factor for cardiomyopathy (odds ratio 0.76, 95% 
confidence interval 0.64 - 0.97, p=0.02) (Table II). 
Discussion
We showed that a lower BMI is associated with cardiomyopathy in 
people living with HIV. HIV infection profoundly affects nutritional 
status because it is associated with poor appetite, impaired nutrient 
absorption, increased basal metabolic rate and opportunistic 
infections.11 Under-nutrition in HIV patients is manifested by weight 
loss, loss of lean body mass and micronutrient deficiencies. We 
compared two groups of HIV-infected individuals who were well 
matched for the stage of HIV disease. The lower BMI is therefore likely 
to be independent of HIV infection, and linked to the cardiac disease.
Cardiac function is both affected by nutrition and can affect 
nutritional status. In a malnourished state, relative cardiac sparing 
occurs – this is especially apparent in chronic disease.11 Cardiac 
sparing occurs to preserve left ventricular function – even in 
patients with severe protein energy malnutrition, ventricular mass 
decreases but the ratio of ventricular mass to body weight remains 
constant. Heart disease can also have an adverse effect on nutritional 
status. Chronic heart dysfunction can result in cardiac cachexia, an 
inappropriate use of lean body mass instead of body fat that results 
in muscle wasting. 
The major limitation of this study is that it cannot determine 
whether the lower BMI in HIV-associated cardiomyopathy is part 
of the causal pathway of cardiomyopathy or an effect of the cardiac 
dysfunction. Furthermore, the potential role of micronutrient 
deficiency in the pathogenesis of the cardiomyopathy was not 
investigated. When attempting to determine nutritional determinants 
of cardiomyopathy, it is important to measure micronutrient levels 
of substances such as selenium, which are implicated in ventricular 
function.12 Although selenium deficiency in healthy humans is 
uncommon, studies have documented a decline in selenium levels in 
the general HIV-infected population, possibly owing to the trapping 
of selenium by a selenoprotein encoded by the proviral genome.13,14 
Low levels of selenium increase the ability of the Coxsackie virus to 
cause cardiac damage and ventricular dysfunction.12 
The role of selenium in the pathogenesis of HIV-associated 
cardiomyopathy has been investigated.5,14,15 Chariot et al. investigated 
the involvement of antioxidant deficiencies in the occurrence 
of cardiac involvement in HIV-infected patients.16 Selenium 
status was significantly lower in the patients compared with the 
controls. Selenium supplementation resulted in echocardiographic 
improvement. There was an improvement of cardiac function after 
selenium supplementation in case reports involving paediatric 
AIDS patients.15 Finally, low selenium levels have been shown 
to be a significant factor in the development of HIV-associated 
cardiomyopathy in black African patients.5
This study extends the observations of micronutrient deficiency 
in HIV-associated cardiomyopathy to include lower BMI, a simple 
clinical measure of nutritional status that can be applied in resource-
poor circumstances of sub-Saharan Africa, which is the epicentre 
of the HIV/AIDS epidemic in the world. Although micronutrient 
measures were not performed in this study, our results are consistent 
with the observation that micronutrient deficiency is predictive of 
cardiomyopathy in people who are living with HIV infection. These 
preliminary findings, taken together with the small trials of selenium 
supplementation in HIV-associated cardiomyopathy, have important 
implications for the development of new therapies in this field. 
The time has come to consider the role of nutritional interventions 
in HIV-associated cardiomyopathy, including the restoration of 
adequate myocyte nutrition as a goal in treating patients suffering 
from HIV-related heart failure. 
This paper is dedicated to the memory of the late Mr Peter Kaye, the 
echocardiographer who worked pro bono on this project. The expert 
assistance and contributions of Sister Maitele Tshifularo, Ms Lebogang 
Montewa, Dr Innocent Monya-Tambi, Ms Terry del Fabbro and Professor 
Gary Maartens are acknowledged with gratitude. The study was funded 
in part by the Medical Research Council and the National Research 
Foundation.
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5.20 (4.6 - 5.64) 4.81 (3.52 - 5.50) 0.22
WHO clinical stage (N (%)) 0.53†
   Stage 1 3 (17.6) 2 (11.1)
   Stage 2 4 (23.5) 6 (33.3)
   Stage 3 5 (29.4) 8 (44.4)
   Stage 4 5 (29.4) 2 (11.1)
NYHA functional class (N (%)) <0.0001†
   Class 1 3 (18.8) 18 (100)
   Class 2 6 (37.5) 0
   Class 3 5 (31.3) 0
   Class 4 2 (12.5) 0
LVEF (median (IQR)) 35.0 (24.3 - 45.0) 69.5 (62.3 - 72.0) <0.0001
LVIDd (median (IQR)) 5.9 (5.4 - 6.4) 4.4 (3.8 - 4.7) <0.0001
BMI (median (IQR)) 20.9 (18.2 - 25.1) 27.0 (21.5 - 29.9) 0.02
MUAC (median (IQR)) 26.2 (22.8 - 30.6) 27.3 (24.2 - 34.2) 0.02
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BF-AMA (median (IQR)) 26.7 (14.5 - 32.0) 32.8 (27.0 - 42.4) 0.02
*Mann-Whitney test, unless otherwise stated.
†χ2 test.
IQR = interquartile range; WHO = World Health Organization; NYHA = New York Heart Association; LVEF = left ventricular ejection fraction; LVIDd = left ventricular internal dimension in 
diastole; BMI = body mass index; MUAC = mid-upper arm circumference; TSF = triceps skin fold thickness; BF-AMA = bone-free arm muscle area (arm muscle circumference).
Table II. Stepwise logistic regression analysis for risk factors 
of dilated cardiomyopathy in HIV-infected patients
Factor OR (95% CI) p-value
BMI 0.76 (0.64 - 0.97) 0.02
CD4 count (cells/μl) 
   <200 0.20 (0.04 - 1.01) 0.05 
   ≥200 1
OR = odds ratio; CI = confidence interval; BMI = body mass index; IQR = interquartile 
range. 
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